Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Waiver Of COX-2 Panel Conflicts Draws More Attention On The Hill

This article was originally published in The Tan Sheet

Executive Summary

FDA advisory committee votes in favor of continued availability of COX-2s in the U.S. are "tainted" due to conflicts of interest among panelists, according to a Feb. 25 letter from Senate Finance Committee Chairman Chuck Grassley (R-Iowa)

You may also be interested in...



Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members

A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said

Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members

A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said

Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members

A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS097929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel